Mutations in Aspergillus fumigatus Resulting in Reduced Susceptibility to Posaconazole Appear To Be Restricted to a Single Amino Acid in the Cytochrome P450 14α-Demethylase
Open Access
- 1 February 2003
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 47 (2) , 577-581
- https://doi.org/10.1128/aac.47.2.577-581.2003
Abstract
To better understand the molecular basis of posaconazole (POS) resistance in Aspergillus fumigatus, resistant laboratory isolates were selected. Spontaneous mutants arose at a frequency of 1 in 108 and fell into two susceptibility groups, moderately resistant and highly resistant. Azole resistance in A. fumigatus was previously associated with decreased drug accumulation. We therefore analyzed the mutants for changes in levels of transcripts of genes encoding efflux pumps (mdr1 and mdr2) and/or alterations in accumulation of [14C]POS. No changes in either pump expression or drug accumulation were detected. Similarly, there was no change in expression of cyp51A or cyp51B, which encode the presumed target site for POS, cytochrome P450 14α-demethylase. DNA sequencing revealed that each resistant isolate carried a single point mutation in residue 54 of cyp51A. Mutations at the same locus were identified in three clinical A. fumigatus isolates exhibiting reduced POS susceptibility but not in susceptible clinical strains. To verify that these mutations were responsible for the resistance phenotype, we introduced them into the chromosome of a POS-susceptible A. fumigatus strain under the control of the glyceraldehyde phosphate dehydrogenase promoter. The transformants exhibited reductions in susceptibility to POS comparable to those exhibited by the original mutants, confirming that point mutations in the cyp51A gene in A. fumigatus can confer reduced susceptibility to POS.Keywords
This publication has 30 references indexed in Scilit:
- Antifungal Activities of Posaconazole, Ravuconazole, and Voriconazole Compared to Those of Itraconazole and Amphotericin B against 239 Clinical Isolates of Aspergillus spp. and Other Filamentous Fungi: Report from SENTRY Antimicrobial Surveillance Program, 2000Antimicrobial Agents and Chemotherapy, 2002
- Molecular basis of resistance to azole antifungalsTrends in Molecular Medicine, 2002
- Comparison of Pathogenesis and Host Immune Responses toCandida glabrataandCandida albicansin Systemically Infected Immunocompetent MiceInfection and Immunity, 2001
- Identification of Two Different 14-α Sterol Demethylase-Related Genes ( cyp51A and cyp51B ) in Aspergillus fumigatus and Other Aspergillus speciesJournal of Clinical Microbiology, 2001
- Antifungal Drug Resistance in AspergillusJournal of Infection, 2000
- Generation of a Complete, Soluble, and Catalytically Active Sterol 14α-Demethylase−Reductase ComplexBiochemistry, 1999
- Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infectionJournal of Antimicrobial Chemotherapy, 1997
- Modeling cytochrome P450 14α demethylase (Candida albicans) from P450camJournal of Molecular Graphics, 1994
- Transformation of Aspergillus niger using the argB gene of Aspergillus nidulansGene, 1985
- Transformation by integration in Aspergillus nidulansGene, 1983